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Background: Low lung function, measured using spirometry, has been associated with mortality from
cardiovascular disease, but whether this is explained by airﬂow obstruction or restriction is a question
that remains unanswered.
Objectives: To assess the association of total lung capacity (TLC), forced vital capacity (FVC) and forced
expiratory volume in 1 s (FEV1) with several cardio-metabolic and inﬂammatory markers.
Methods: In the follow up of the Burden of Lung Disease (BOLD) study in London, acceptable post-
bronchodilator spirometric, pulse rate, pulse wave velocity and blood pressure data were obtained
from 108 participants. Blood samples for measurement of cardio-metabolic and inﬂammatory markers
were also collected from these participants. Association of lung function and volume with the different
biomarkers was examined in multivariable linear regression models adjusted for potential confounders.
Results: Following adjustment for age, sex, height, and ethnicity, TLC (adjusted coefﬁcient ¼ 1.53; 95%
CI: 2.57, 0.49) and FVC (adjusted coefﬁcient ¼ 2.66; 95% CI: 4.98, 0.34) were inversely associated
with pulse wave velocity, and further adjustment for smoking status, pack-years and body mass index
(BMI) did not materially change these results. FEV1 was inversely associated with systolic blood pressure,
and adjustment for smoking status, pack-years and BMI made this association stronger (adjusted
coefﬁcient ¼ 9.47; 95% CI: 15.62, 3.32).
Conclusion: The inverse association of pulse wave velocity, which is a marker of cardiovascular disease,
with TLC suggests that the association of the former with low FVC is independent of airﬂow obstruction.
The association between FEV1 with systolic blood pressure after adjustment for FVC suggests an asso-
ciation with airﬂow obstruction rather than with restricted spirometry.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Low lung function has been associated with increased mortality,
including mortality from cardiovascular disease [1e4]. Although
many authors have linked this to airﬂow obstruction, because of the
connection with forced expiratory volume in 1 s (FEV1), those that
have looked separately at forced vital capacity (FVC) and at these
two measures analysed together have shown that the strong as-
sociation is between mortality and FVC, not airﬂow obstruction [5].
Similarly, several of the co-morbidities associated with cardiovas-
cular diseases (e.g. impaired glucose tolerance, hypertension, and
obesity) have been shown to associatewith low FVC [6,7]. However,
interpretation is complicated by the increased residual volume in, Occupational Medicine and
erial College Emmanuel Kaye
aral).
Ltd. This is an open access articlemore severe obstructionwhich may also lead to a reduction in FVC.
Few population-based studies have speciﬁcally tested the as-
sociation of cardio-metabolic and inﬂammatory markers with lung
function. The Whitehall II Study and the Caerphilly Prospective
Study reported an inverse association between pulse wave velocity
and FVC and/or FEV1 [8,9]. The US Third National Health and
Nutrition Examination Survey (NHANES III) reported an inverse
association between pulse pressure and FEV1 [10]. The Multiethnic
Study of Atherosclerosis (MESA) reported that both FEV1 and FVC
are positively associated with small artery elasticity, and inversely
associated with serum markers of endothelial dysfunction and
inﬂammation such as intercellular adhesion molecule 1 (ICAM-1),
ﬁbrinogen, C-reactive protein (CRP), and interleukin 6 (IL-6) [11].
The NHANES III and the Korean National Health and Nutrition Ex-
amination Survey (KNHANES) have both reported an inverse as-
sociation between glycated haemoglobin (HbA1c) and both FEV1
and FVC [12,13].under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ation of cardio-metabolic or inﬂammatory markers with total lung
capacity (TLC), which would be relevant to the interpretation of
ﬁndings carried out using FVC, especially when there is some evi-
dence suggesting that the TLC might be a better predictor of mor-
tality and hospitalisation than the FVC in older people [14].
The main aim of the present analysis was to assess the associ-
ation of TLC with several cardio-metabolic and inﬂammatory
markers, as surrogate outcomes for cardiovascular disease. It was
also our aim to examine whether FVC is a good substitute of TLC in
predicting the levels of thesemarkers. To achieve our aims, we have
measured the associations of the different cardio-metabolic and
inﬂammatory markers with TLC, FVC and FEV1 in participants who
took part in the follow up of the UK arm of the Burden of
Obstructive Lung Disease (BOLD) study, and tested whether these
simply reﬂect a common association with smoking and body mass
index (BMI).
1. Methods
1.1. Study participants
The design and rationale for the multicentre BOLD study and its
UK arm have been reported elsewhere [15,16]. Brieﬂy, in 2006 non-
institutionalised adults aged 40 years and older were sampled from
the lists of three general practices in the Borough of Hammersmith
and Fulham, London, and invited to take part in the study. This
selection process led to 677 participants in the study. In 2011, 636
(94%) participants, who agreed in 2006 to take part in a follow up,
were again approached and 281 (42%) responded to a postal
questionnaire and attended the clinic for further lung function
measurements (Fig. 1). These were split into two groups based onBOLD London
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Fig. 1. Participants from the Burden of Lung Diseatheir characteristics in 2006: 1) participants at high risk of an
abnormal lung function [i.e. those who have had an FEV1/
FVC < lower limit of normal (LLN) (n ¼ 34), FVC < LLN (n ¼ 23), or
who have reported an history of either emphysema (n ¼ 6) or past
tuberculosis (n ¼ 5)]; 2) all other eligible participants. The ﬁrst
group (n ¼ 68) and a random sample of the second group (n ¼ 40),
stratiﬁed by age, sex and ethnicity, completed the same long pro-
tocol. The rest of participants completed a short protocol of just the
modiﬁed questionnaire and pre- and post-bronchodilator spirom-
etry (n ¼ 173). This report is based on data just from participants
who completed the long version of the BOLD protocol. This
comprehensive protocol involved the collection of information on
basic demographics, smoking habits, history of respiratory symp-
toms and co-morbidities, use of respiratory medication, risk factors
for chronic obstructive pulmonary disease, healthcare utilisation,
occupational exposures [15], and diet, the collection of blood for
measurement of biomarkers, spirometry for measurement of lung
function, and body plethysmography for measurement of lung
volumes. Ethical approval for the follow up study was obtained
from the National Research Ethics Service (Oxfordshire REC C), and
all participants provided written informed consent.
1.2. Cardio-metabolic, inﬂammatory and other serum markers
Pulse rate, pulse wave velocity, and systolic and diastolic blood
pressures were measured using a Vicorder (Skidmore Medical,
Bristol, UK). Blood was collected for routine measurement of white
blood cells and HbA1c, and for measurement of other serum
markers. Cytokines and inﬂammatory markers [CRP, interleukin 8
(IL-8), IL-6, tumour necrosis factor alpha (TNF-alpha), myeloper-
oxidase (MPO)], markers of vascular injury [vascular cell adhesion
protein 1 (VCAM-1), ICAM-1, serum amyloid A (SAA)], proteinasescould not be traced
fused to take part
changed address
 did not reply
 responded to postal questionnaire,
 did not attend the clinic
nction
ol)
andom sample of 173 had normal lung function,
 did not complete the long protocol
se London follow-up included in this report.
Table 1
Characteristics of the participants in the BOLD London Follow up who completed the long protocol.
Abnormal lung function (N ¼ 68) Normal lung function (N ¼ 40) Total (N ¼ 108)
Age (years), median (IQR) 58 (51e67) 60.5 (51e65) 59 (51e67)
Sex (%)
Females 40 (59) 23 (58) 63 (58)
Males 28 (41) 17 (42) 45 (42)
Ethnicity (%)
White 49 (72) 36 (90) 85 (79)
Other 19 (28) 4 (10) 23 (21)
Height (cm), median (IQR) 165 (159e171) 168 (159e174) 168 (161e175)
Body mass index (kg/m2), median (IQR) 25.7 (23.1e31.6) 27.8 (24.4e30.7) 26.4 (23.6e29.8)
Pack-years of smoking, median (IQR) 12.6 (0e31.4) 1.18 (0e13.5) 4.7 (0e20.6)
TLC (L), median (IQR) 5.62 (4.84e6.46) 5.72 (4.77e6.59) 5.65 (4.76e6.43)
FVC (L), median (IQR) 3.22 (2.54e3.70) 3.22 (2.91e4.07) 3.22 (2.72e4.53)
FVC % predicted, median (IQR) 83.5 (75.1e102.2) 98.1 (89.9e105.0) 92.0 (78.1e104.0)
FEV1 (L/s), median (IQR) 2.05 (1.60 2.50) 2.50 (2.24e3.08) 2.46 (2.04e3.03)
FEV1% predicted, median (IQR) 73.4 (63.8e82.7) 91.2 (81.8e97.7) 79.4 (69.9e91.7)
Pulse rate (beats/min), median (IQR) 70 (64e76) 68 (61e74) 68 (63e76)
Pulse wave velocity (m/s), median (IQR) 9 (7e11) 9 (8e12) 9 (8e11)
Systolic blood pressure (mm Hg), median (IQR) 140 (127e151) 139 (130e146) 140 (129e148)
Diastolic blood pressure (mm Hg), median (IQR) 78 (72e81) 76 (70e82) 78 (72e82)
White blood cell count (x109/L), median (IQR) 6.35 (5.4e7.3) 5.6 (5e6.9) 6.0 (5.1e7.3)
HbA1c (%), median (IQR) 5.65 (5.4e5.9) 5.6 (5.3e5.7) 5.6 (5.4e5.8)
C-reactive protein (mg/mL), median (IQR) 1.19 (0.41e3.17) 0.82 (0.36e2.61) 1.01 (0.36e2.63)
IL-8 (pg/mL), median (IQR) 4.99 (3.80e6.74) 5.24 (4.05e6.99) 5.15 (3.89e6.99)
IL-6 (pg/mL), median (IQR) 1.03 (0.70e1.43) 0.98 (0.63e1.81) 1.02 (0.71e1.69)
TNF-alpha (pg/mL), median (IQR) 3.44 (2.37e4.44) 3.69 (2.52e5.46) 3.62 (2.43e5.29)
MPO (ng/mL), median (IQR) 0.35 (0.26e0.54) 0.32 (0.20e0.63) 0.35 (0.24e0.55)
VCAM-1 (ng/mL), median (IQR) 226.0 (186.4e272.6) 206.0 (181.0e224.4) 214.5 (181.0e262.6)
ICAM-1 (ng/mL), median (IQR) 146.6 (120.0e193.3) 134.7 (112.0e156.6) 139.0 (112.8e167.2)
SAA (mg/mL), median (IQR) 0.68 (0.41e1.20) 0.67 (0.45e1.03) 0.68 (0.41e1.11)
MMP-3 (ng/mL), median (IQR) 11.42 (7.44e16.77) 12.10 (7.34e15.17) 11.99 (7.69e18.19)
MMP-9 (ng/mL), median (IQR) 48.46 (32.92e69.33) 40.65 (26.02e57.88) 45.43 (29.88e66.05)
TIMP-1 (ng/mL), median (IQR) 28.38 (22.06e34.83) 26.43 (23.17e31.68) 26.90 (21.73e33.51)
IQR, interquartile range. TLC, total lung capacity. FVC, forced vital capacity. FEV1, forced expiratory volume in 1 s. HbA1c, glycated haemoglobin. IL-8, interleukin 8. IL-6,
interleukin 6. TNF-alpha, tumour necrosis factor alpha. MPO, myeloperoxidase. VCAM-1, vascular cell adhesion protein 1. ICAM-1, intercellular adhesion molecule 1. SAA,
serum amyloid A. MMP-3, matrix metalloproteinase 3. MMP-9, matrix metalloproteinase 9. TIMP-1, tissue inhibitor of metalloproteinase 1.
Table 2
Association of cardio-metabolic markers with total lung capacity (TLC).
Cardio-metabolic markers Unadjusted coefﬁcient
(95% CI)
P Adjusted coefﬁcient*
(95% CI)
P Adjusted coefﬁcient**
(95% CI)
P Adjusted coefﬁcient***
(95% CI)
P
Pulse rate (beats/min) 0.54
(2.47, 1.40)
0.58 1.02
(4.16, 2.13)
0.52 0.79
(3.96, 2.39)
0.62 0.45
(3.32, 2.42)
0.75
Pulse wave velocity (m/s) 0.27
(1.01, 0.47)
0.47 1.53
(2.57, 0.49)
<0.001 1.49
(2.45, 0.52)
<0.001 1.29
(2.19, 0.39)
0.01
Systolic blood pressure (mm Hg) 2.02
(4.66, 0.62)
0.13 1.81
(4.90, 1.28)
0.25 1.84
(5.00, 1.31)
0.25 1.00
(4.63, 2.63)
0.59
Diastolic blood pressure (mm Hg) 0.88
(0.80, 2.55)
0.30 0.10
(2.14, 1.94)
0.92 0.20
(2.24, 1.84)
0.85 0.26
(1.91, 2.42)
0.81
White blood cell count (x109/L) 0.05
(0.37, 0.28)
0.78 0.15
(0.59, 0.30)
0.52 0.15
(0.59, 0.30)
0.51 0.04
(0.41, 0.50)
0.85
HbA1c (%) 0.09
(0.17, 0.001)
0.05 0.08
(0.23, 0.06)
0.27 0.08
(0.22, 0.06)
0.24 0.03
(0.16, 0.10)
0.65
C-reactive protein (mg/mL) 0.13
(0.62, 0.36)
0.61 0.06
(0.74, 0.62)
0.86 0.09
(0.79, 0.61)
0.80 0.31
(0.31, 0.93)
0.32
IL-8 (pg/mL) 0.23
(0.29, 0.75)
0.39 0.38
(0.32, 1.09)
0.29 0.37
(0.35, 1.09)
0.31 0.28
(0.34, 0.90)
0.37
IL-6 (pg/mL) 0.25
(0.86, 0.35)
0.41 0.24
(0.70, 0.21)
0.29 0.26
(0.74, 0.21)
0.28 0.10
(0.52, 0.31)
0.62
TNF-alpha (pg/mL) 0.28
(0.14, 0.70)
0.18 0.30
(0.37, 0.98)
0.38 0.31
(0.37, 0.99)
0.37 0.15
(0.44, 0.74)
0.61
MPO (ng/mL) 0.02
(0.02, 0.06)
0.33 0.03
(0.11, 0.05)
0.50 0.03
(0.11, 0.05)
0.48 0.00
(0.07, 0.07)
1.00
VCAM-1 (ng/mL) 0.58
(16.16, 14.99)
0.94 1.73
(23.28, 19.82)
0.87 1.89
(23.38, 19.61)
0.86 4.35
(15.05, 23.75)
0.66
ICAM-1 (ng/mL) 5.31
(2.60, 13.23)
0.19 9.80
(2.46, 22.06)
0.12 9.23
(2.94, 21.39)
0.14 8.36
(1.90, 18.61)
0.11
SAA (mg/mL) 0.16
(0.35, 0.66)
0.54 0.24
(0.32, 0.81)
0.40 0.24
(0.33, 0.82)
0.40 0.32
(0.18, 0.82)
0.20
MMP-3 (ng/mL) 1.06
(0.71, 2.84)
0.24 0.78
(3.55, 1.99)
0.58 0.79
(3.57, 1.98)
0.57 0.35
(2.61, 2.54)
0.98
MMP-9 (ng/mL) 4.08
(3.67, 11.82)
0.30 1.67
(10.51, 13.85)
0.79 1.59
(10.69, 13.87)
0.80 1.92
(9.91, 13.75)
0.75
TIMP-1 (ng/mL) 1.03
(0.56, 2.62)
0.20 1.18
(0.90, 3.25)
0.26 1.18
(0.88, 3.23)
0.26 1.43
(0.44, 3.23)
0.13
*Adjusted for age, sex, height, and ethnicity. **Adjusted for age, sex, height, ethnicity, smoking status and pack-years. ***Adjusted for age, sex, ethnicity, smoking status, pack-
years, and body mass index.
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metalloproteinase 9 (MMP-9) and tissue inhibitor of metal-
loproteinase 1 (TIMP-1)], were measured in serum samples using a
MULTI-ARRAY® assay system according to the manufacturer's in-
structions (Meso Scale Discovery, Gaithersburg, MD, USA).
1.3. Lung measurements
TLC was measured at Charing Cross Hospital using body pleth-
ysmography following the ATS/ERS criteria [17]. FEV1 and FVCwere
measured in the same facility by a trained member of the BOLD
team using the ndd EasyOne Spirometer (ndd Medizintechnik AG,
Zurich, Switzerland), before and 15 min after administration of
salbutamol (200 mg) from a metred dose inhaler through a spacer.
The BOLD Pulmonary Function Reading Centre reviewed each spi-
rogram and assigned them a quality score based on acceptability
and reproducibility criteria from the American Thoracic Society
(ATS) and European Respiratory Society (ERS) [18].
1.4. Statistical methods
Statistical analyses were performed using Stata V.12.1 (Stata-
Corp LP, College Station, TX). The set of commands for surveys
(‘svy’) were used to take into account the sampling design and
correct for the effect of clustering. To examine the association of
each of the cardio-metabolic and inﬂammatory markers with each
of the lung function measurements, multivariable linear regression
models, allowing for sample weights derived by estimating the
probability of selection, were used. These models were adjusted forTable 3
Association of cardio-metabolic markers with forced vital capacity (FVC).
Cardio-metabolic markers Unadjusted coefﬁcient
(95% CI)
P Adjusted coe
(95% CI)
Pulse rate (beats/min) 0.16
(2.50, 2.82)
0.91 1.51
(8.20, 5.18)
Pulse wave velocity (m/s) 0.28
(1.47, 0.91)
0.64 2.66
(4.98, 0.34
Systolic blood pressure (mm Hg) 5.20
(9.30, 1.10)
0.01 0.30
(8.06, 7.45)
Diastolic blood pressure (mm Hg) 0.07
(1.99, 2.12)
0.95 2.18
(7.40, 3.03)
White blood cell count (x109/L) 0.03
(0.46, 0.39)
0.88 0.48
(0.46, 1.42)
HbA1c (%) 0.12
(0.28, 0.04)
0.15 0.23
(0.53, 0.06)
C-reactive protein (mg/mL) 0.36
(1.03, 0.31)
0.29 0.95
(2.74, 0.85)
IL-8 (pg/mL) 0.20
(0.99, 0.60)
0.63 0.99
(2.55, 0.57)
IL-6 (pg/mL) 0.48
(1.34, 0.39)
0.28 0.95
(2.12, 0.21)
TNF-alpha (pg/mL) 0.18
(0.81, 0.44)
0.56 0.71
(2.28, 0.86)
MPO (ng/mL) 0.00
(0.06, 0.07)
0.90 0.13
(0.30, 0.03)
VCAM-1 (ng/mL) 13.76
(36.29, 8.76)
0.23 14.23
(67.21, 38.7
ICAM-1 (ng/mL) 1.66
(14.51, 11.20)
0.80 13.94
(14.87, 42.7
SAA (mg/mL) 0.13
(0.51, 0.76)
0.69 0.25
(0.54, 1.05)
MMP-3 (ng/mL) 2.64
(0.89, 4.39)
<0.001 3.94
(1.29, 9.17)
MMP-9 (ng/mL) 2.76
(6.21, 11.73)
0.54 17.61
(11.44, 46.6
TIMP-1 (ng/mL) 0.14
(2.36, 2.63)
0.91 3.80
(3.39, 11.00
*Adjusted for age, sex, height, ethnicity, and forced expiratory volume in 1 s (FEV1). **Adju
for age, sex, ethnicity, FEV1, smoking status, pack-years, and body mass index.age, sex, height, and ethnicity. The models for FEV1 (or FVC) were
also adjusted for FVC (or FEV1). All models were further adjusted
for smoking status and pack-years and BMI. Results were consid-
ered statistically signiﬁcant when P was equal or less than 0.05.
2. Results
Of the 108 participants who responded to the postal question-
naire and attended the clinic for further lung function measure-
ments, 55.7% were females, 84% were white, and their median age
was 59 years. The median TLC, FVC, and FEV1 of these participants
was 5.65 L, 3.32 L, and 2.46 L, respectively. A description of the
characteristics of the participants in this study is presented in
Table 1.
Tables 2e4 show the unadjusted and adjusted regression co-
efﬁcients, with 95% conﬁdence intervals (CIs), for the association of
TLC, FVC and FEV1 with the different cardio-metabolic and in-
ﬂammatory markers.
After adjustment for age, sex, height, and ethnicity (and FEV1 in
models for FVC), both TLC (adjusted coefﬁcient ¼ 1.53; 95%
CI: 2.57, 0.49) and FVC (adjusted coefﬁcient ¼ 2.66; 95%
CI: 4.98, 0.34) were inversely associated with pulse wave ve-
locity. Further adjustment for smoking status, pack-years and BMI
did not materially change these results (Tables 2 and 3; Figs. 2 and
3). Although FVC was highly correlated with TLC (correlation
coefﬁcient ¼ 0.77, P < 0.001), the model for the association of pulse
wave velocity with TLC (r-squared ¼ 0.22) had a better ﬁt than the
one for FVC (r-squared ¼ 0.10). TLC was associated with HbA1c
(unadjusted coefﬁcient ¼ 0.09; 95% CI: 0.17, 0.001), but afterfﬁcient* P Adjusted coefﬁcient**
(95% CI)
P Adjusted coefﬁcient***
(95% CI)
P
0.65 1.92
(8.74, 4.90)
0.58 0.82
(7.81, 6.17)
0.82
)
0.03 2.98
(5.31, 0.65)
0.01 2.85
(5.59, 0.11)
0.04
0.94 0.10
(7.58, 7.37)
0.98 5.43
(1.90, 12.76)
0.14
0.41 1.30
(6.53, 3.93)
0.62 2.59
(2.67, 7.84)
0.33
0.31 0.36
(0.65, 1.37)
0.48 0.66
(0.36, 1.67)
0.20
0.12 0.28
(0.58, 0.01)
0.06 0.09
(0.40, 0.21)
0.54
0.30 1.23
(3.00, 0.54)
0.17 0.52
(0.71, 1.75)
0.40
0.21 1.12
(2.75, 0.35)
0.18 1.05
(2.67, 0.57)
0.20
0.11 1.04
(2.43, 0.35)
0.14 0.61
(1.62, 0.40)
0.24
0.37 0.77
(2.36, 0.82)
0.34 1.10
(2.43, 0.23)
0.11
0.10 0.13
(0.28, 0.02)
0.09 0.09
(0.23, 0.05)
0.19
6)
0.60 15.62
(67.63, 36.38)
0.55 10.93
(24.47, 46.34)
0.54
4)
0.34 8.67
(20.88, 38.21)
0.56 12.34
(13.71, 38.39)
0.35
0.53 0.44
(0.73, 0.60)
0.46 0.76
(0.20, 1.72)
0.12
0.14 4.23
(1.14, 9.60)
0.12 4.16
(1.26, 9.57)
0.13
5)
0.23 15.86
(15.67, 47.39)
0.32 17.10
(16.59, 50.79)
0.32
)
0.30 2.68
(4.18, 9.54)
0.44 3.61
(2.62, 9.83)
0.25
sted for age, sex, height, ethnicity, FEV1, smoking status and pack-years. ***Adjusted
Table 4
Association of cardio-metabolic markers with forced expiratory volume in 1 s (FEV1).
Cardio-metabolic markers Unadjusted coefﬁcient
(95% CI)
P Adjusted coefﬁcient*
(95% CI)
P Adjusted coefﬁcient**
(95% CI)
P Adjusted coefﬁcient***
(95% CI)
P
Pulse rate (beats/min) 0.25
(2.84, 3.34)
0.87 0.08
(6.62, 6.46)
0.98 0.81
(6.57, 8.18)
0.83 0.33
(7.30, 7.97)
0.93
Pulse wave velocity (m/s) 0.11
(1.38, 1.16)
0.86 1.80
(0.54, 4.14)
0.13 2.07
(0.36, 4.51)
0.09 2.12
(0.37, 4.60)
0.09
Systolic blood pressure (mm Hg) 7.67
(12.14, - 3.20)
<0.001 7.02
(12.58, 1.46)
0.01 8.71
(14.77, 2.64)
0.01 9.47
(15.62, 3.32)
<0.001
Diastolic blood pressure (mm Hg) 0.01
(2.29, 2.31)
0.99 1.38
(6.41, 3.65)
0.59 3.54
(8.85, 1.77)
0.19 4.17
(9.80, 1.46)
0.14
White blood cell count (x109/L) 0.30
(0.81, 0.21)
0.25 0.66
(1.64, 0.32)
0.19 0.43
(1.61, 0.76)
0.48 0.72
(1.92, 0.49)
0.24
HbA1c (%) 0.12
(0.28, 0.04)
0.13 0.001
(0.24, 0.24)
0.99 0.10
(0.14, 0.34)
0.40 0.04
(0.28, 0.19)
0.71
C-reactive protein (mg/mL) 0.63
(1.46, 0.20)
0.14 0.40
(1.69, 2.50)
0.70 0.13
(0.08, 3.33)
0.23 0.32
(1.55, 2.18)
0.74
IL-8 (pg/mL) 0.15
(1.01, 0.70)
0.72 0.69
(2.45, 1.07)
0.44 0.56
(2.56, 1.45)
0.58 0.39
(2.57, 1.79)
0.72
IL-6 (pg/mL) 0.43
(1.14, 0.28)
0.23 0.14
(0.55, 0.83)
0.69 0.46
(0.36, 1.27)
0.27 0.38
(0.41, 1.17)
0.34
TNF-alpha (pg/mL) 0.30
(1.05, 0.45)
0.43 0.51
(2.06, 1.04)
0.51 0.65
(2.49, 1.20)
0.49 0.18
(2.17, 1.82)
0.86
MPO (ng/mL) 0.03
(0.04, 0.09)
0.41 0.07
(0.08, 0.22)
0.33 0.07
(0.08, 0.23)
0.36 0.07
(0.09, 0.23)
0.38
VCAM-1 (ng/mL) 23.72
(49.17, 1.73)
0.07 18.85
(85.11, 47.41)
0.57 14.61
(81.68, 52.47)
0.67 28.21
(95.12, 38.69)
0.40
ICAM-1 (ng/mL) 8.23
(23.95, 7.49)
0.30 27.73
(60.50, 5.04)
0.10 13.96
(48.14, 20.23)
0.42 19.93
(56.76, 16.90)
0.29
SAA (mg/mL) 0.01
(0.67, 0.69)
0.97 0.57
(0.43, 1.58)
0.26 0.39
(0.32, 1.11)
0.28 0.10
(0.57, 0.76)
0.78
MMP-3 (ng/mL) 1.49
(0.37, 3.35)
0.12 4.73
(10.58, 1.12)
0.11 5.51
(11.63, 0.60)
0.08 4.82
(11.03, 1.39)
0.13
MMP-9 (ng/mL) 4.96
(12.79, 2.87)
0.21 24.85
(58.59, 8.88)
0.15 21.71
(59.19, 15.77)
0.25 21.48
(60.15, 17.19)
0.27
TIMP-1 (ng/mL) 1.29
(3.59, 1.01)
0.27 2.81
(7.79, 2.17)
0.27 1.11
(5.74, 3.52)
0.63 2.12
(7.03, 2.79)
0.39
*Adjusted for age, sex, height, ethnicity, and forced vital capacity (FVC).**Adjusted for age, sex, height, ethnicity, FVC, smoking status and pack-years. ***Adjusted for age, sex,
ethnicity, FVC, smoking status, pack-years, and body mass index.
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was associated with systolic blood pressure (unadjusted
coefﬁcient ¼ 5.20; 95% CI: 9.30, 1.10) and MMP-3 (unadjusted
coefﬁcient ¼ 2.64; 95% CI: 0.89, 4.39), but after adjustment for
confounders these associations became non-signiﬁcant (Table 3).
There was a borderline signiﬁcant association of FVC with HbA1c
after adjustment for age, sex, height, ethnicity, FEV1 and smoking
(adjusted coefﬁcient ¼ 0.28; 95% CI: 0.58, 0.01), but this dis-
appeared after including BMI in the model (adjusted0
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Fig. 2. Association of pulse wave velocity with total lung capacity, adjusted for age, sex,
ethnicity, smoking pack-years, and body mass index.coefﬁcient ¼ 0.09; 95% CI: 0.40, 0.21). FVC and TLC were not
signiﬁcantly associated with any other cardio-metabolic or in-
ﬂammatory marker measured.
FEV1 was inversely associated with systolic blood pressure
(unadjusted coefﬁcient ¼ 7.67; 95% CI: 12.14, 3.20), even after
adjustment for age, sex, height, ethnicity and FVC (adjusted
coefﬁcient ¼ 7.02; 95% CI: 12.58, 1.46), smoking status and
pack-years (adjusted coefﬁcient ¼ 8.71; 95% CI: 14.77, 2.64)
and BMI (adjusted coefﬁcient ¼ 9.47; 95% CI: 15.62, 3.32).0
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Fig. 3. Association of pulse wave velocity with forced vital capacity, adjusted for age,
sex, ethnicity, smoking pack-years, and body mass index.
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metabolic marker (Table 4).
In sensitivity analyses with fully adjusted models but excluding
participants with abnormal lung function, the associations of pulse
wave velocity with TLC (adjusted coefﬁcient¼1.70; 95% CI:3.78,
0.39) and FVC (adjusted coefﬁcient ¼ 5.17; 95% CI: 16.98, 6.65)
were strengthenedbut not signiﬁcant, and the associationof systolic
blood pressure with FEV1 (adjusted coefﬁcient ¼ 26.97; 95%
CI: 43.97, 9.98) was strengthened and signiﬁcant.
3. Discussion
In this population-based study, we observed little association
between the several cardio-metabolic markers and measures of
lung function and volume. However, after adjustment for con-
founders, FEV1 was inversely associated with systolic blood pres-
sure, and both TLC and FVC were inversely associated with pulse
wave velocity, a marker of arterial stiffness. This condition is an
important risk factor for cardiovascular disease and mortality even
among apparently healthy people, and has been associated with
atherosclerosis and left ventricular hypertrophy, which is a risk
factor for congestive heart failure [19e21].
The strengths of this study are the use of a standardised ques-
tionnaire for assessment of risk factors and high quality protocol for
spirometry, the use of post- instead of pre-bronchodilator spiro-
metric measurements, and the use of body plethysmography to
measure TLC, which is rare in epidemiological studies. In people
with severe obstruction a signiﬁcant quantity of air may remain
trapped during the spirometric forced expiratory manoeuvre,
increasing the residual volume and decreasing the FVC, which
would incorrectly suggest the presence of restriction. The mea-
surement of TLC using plethysmography, which is independent of
the forced expiratorymanoeuvre, allows identiﬁcation of true cases
of lung restriction. Body plethysmography is a highly informative
method to assess airway obstruction and lung volumes [22], but
because it needs to be carried out in a clinical setting and it is
technically demanding it is not commonly used in large studies. The
main limitations are: 1) the small number of subjects in the anal-
ysis, as compared to the initial sample in BOLD London; and 2) the
non-longitudinal nature of the present analysis, which prevents us
from drawing strong conclusions in terms of temporality. This small
sample size was partly by design and partly the result of a very
itinerant population and a general lack of interest for surveys in
large cities, such as London, which both reduce response rates. We
used sampling weights to mitigate the effects of cohort attrition
and to allow for the oversampling of those with abnormal
spirometry at the ﬁrst visit.
To our knowledge this is the ﬁrst study to report an inverse
association between TLC and pulse wave velocity. However,
reduced TLC has been previously associated with overall mortality
in an Italian study of elderly participants without airway obstruc-
tion [14].
The inverse association of FVC with pulse wave velocity agrees
with previous reports, such as those from theWhitehall II Study [9],
the Caerphilly Prospective Study [8], and MESA (used artery elas-
ticity instead of pulse wave velocity) [11]. Our ﬁnding of an inverse
association of FEV1 with systolic blood pressure is consistent with
previous reports, such as those from the Cardiovascular Health
Study [23], NHANES III (used pulse rate instead of systolic blood
pressure) [10], Coronary Artery Risk Development in Young Adults
[7], and Prospective Urban and Rural Epidemiological Study in
South Africa [24].
After adjustment for several confounders, we found no signiﬁ-
cant associations between TLC or FVC or FEV1 with markers of
inﬂammation, vascular injury or HbA1c. This is in contrast withresults fromMESA, which reported inverse associations of both FVC
and FEV1 with ICAM-1, CRP, and IL-6 [11], and fromNHANES III [12]
and KNHANESwhich have reported an inverse association between
the two spirometric measures and HbA1c [13]. However, our study
is smaller than the previous ones and random error in such mea-
surements may explain the lack of signiﬁcant associations with the
markers of inﬂammation, vascular injury and insulin resistance.
The lack of evidence for a strong association of lung function
with these markers suggests that the association of lung function
with systolic blood pressure and arterial stiffness is not mediated
by either inﬂammation or insulin resistance. However, this does not
exclude the possibility that other cardio-metabolic or inﬂammatory
makers may be involved in the underlying mechanisms that link
lung function and arterial stiffness or that a low lung function may
lead to a high systolic blood pressure and pulse wave velocity. In a
population-based study with adults free of coronary heart disease
and stroke at baseline, low peak expiratory ﬂow was reported as a
good predictor of carotid atherosclerosis at four years of follow up
[25]. The Caerphilly Prospective Study has reported that early lung
function measurements compared to later life measurements are
strong predictors of arterial stiffness [8].
In conclusion, our ﬁndings show that reduced TLC and FVC,
which correlate to each other very well, are associated with higher
pulse wave velocity, a marker of atherosclerotic changes, but the ﬁt
of themodel using TLC is much better. This supports the impression
that the association between mortality and a low FVC is reﬂecting a
more basic association with a low TLC and may explain why as
populations age or become sicker the TLC is better predictor of
future mortality [14]. This also adds to the evidence that the rela-
tionship between low lung function and cardiovascular disease is
largely independent of airway obstruction, althoughwe found FEV1
to inversely associate with systolic blood pressure. Large longitu-
dinal studies are needed to establish whether or not low lung
function precedes cardiovascular disease and mortality.
Author contribution
Conception and design: PGJB; Analysis and interpretation: AFSA,
JP, MJ, PGJB; Drafting the manuscript: AFSA; Critical revision of the
manuscript: AFSA, JP, LG, MJ, PGJB.
Acknowledgements
We would like to thank the participants, ﬁeld workers, lab
technicians and data managers of the BOLD London, and in
particular Fiona McLean, Jane Cameron, Michael Tumilty and
Anamika Jithoo, for their time and dedication to this study. In
addition we would like to thank Dr Kevin Murphy and Hannah
Tighe, from Charing Cross Hospital, for the loan of and help with
plethysmography equipment, and Simon Dickinson, from SMART
Medical, for the loan of the Vicorder. This study was funded by the
UK Department of Health Policy Research Programme (0120016)
and the Wellcome Trust (085790/Z/08/Z).
References
[1] D.D. Sin, N.R. Anthonisen, J.B. Soriano, A.G. Agusti, Mortality in COPD: role of
comorbidities, Eur. Respir. J. 28 (2006) 1245e1257.
[2] W.B. Kannel, H. Hubert, E.A. Lew, Vital Capacity as a predictor of
cardiovascular-disease e the framingham-study, Am. Heart J. 105 (1983)
311e315.
[3] L.P. Fried, R.A. Kronmal, A.B. Newman, D.E. Bild, M.B. Mittelmark, J.F. Polak, et
al., Risk factors for 5-year mortality in older adults e the cardiovascular health
study, Jama-Journal Am. Med. Assoc. 279 (1998) 585e592.
[4] H.J. Schunemann, J. Dorn, B.J.B. Grant, W. Winkelstein, M. Trevisan, Pulmonary
function is a long-term predictor of mortality in the general population e 29-
year follow-up of the Buffalo Health Study, Chest 118 (2000) 656e664.
A.F.S. Amaral et al. / Respiratory Medicine 109 (2015) 1569e1575 1575[5] P.G. Burney, R. Hooper, Forced vital capacity, airway obstruction and survival
in a general population sample from the USA, Thorax 66 (2011) 49e54.
[6] C.H. Kim, H.K. Kim, E.H. Kim, S.J. Bae, Y.J. Jung, J. Choi, et al., Association of
restrictive ventilatory dysfunction with the development of prediabetes and
type 2 diabetes in Koreans, Acta Diabetol. 52 (2014) 357e363.
[7] D.R. Jacobs Jr., H. Yatsuya, M.O. Hearst, B. Thyagarajan, R. Kalhan, S. Rosenberg,
et al., Rate of decline of forced vital capacity predicts future arterial hyper-
tension: the Coronary Artery Risk Development in Young Adults Study, Hy-
pertension 59 (2012) 219e225.
[8] C.E. Bolton, J.R. Cockcroft, R. Sabit, M. Munnery, C.M. McEniery, I.B. Wilkinson,
et al., Lung function in mid-life compared with later life is a stronger predictor
of arterial stiffness in men: the Caerphilly Prospective Study, Int. J. Epidemiol.
38 (2009) 867e876.
[9] E.J. Brunner, M.J. Shipley, D.R. Witte, A. Singh-Manoux, A.R. Britton, A.G. Tabak,
et al., Arterial stiffness, physical function, and functional limitation: the
Whitehall II Study, Hypertension 57 (2011) 1003e1009.
[10] M.D. Jankowich, T. Taveira, W.C. Wu, Decreased lung function is associated
with increased arterial stiffness as measured by peripheral pulse pressure:
data from NHANES III, Am. J. Hypertens. 23 (2010) 614e619.
[11] D.A. Duprez, M.O. Hearst, P.L. Lutsey, D.M. Herrington, P. Ouyang, R.G. Barr, et
al., Associations among lung function, arterial elasticity, and circulating
endothelial and inﬂammation markers: the multiethnic study of atheroscle-
rosis, Hypertension 61 (2013) 542e548.
[12] T.M. McKeever, P.J. Weston, R. Hubbard, A. Fogarty, Lung function and glucose
metabolism: an analysis of data from the Third National Health and Nutrition
Examination Survey, Am. J. Epidemiol. 161 (2005) 546e556.
[13] I.H. Oh, J.H. Park, C.H. Lee, J.S. Park, The association of normal range glycated
hemoglobin with restrictive lung pattern in the general population, PLoS One
10 (2015) e0117725.
[14] C. Pedone, S. Scarlata, D. Chiurco, M.E. Conte, F. Forastiere, R. Antonelli-Incalzi,
Association of reduced total lung capacity with mortality and use of health
services, Chest 141 (2012) 1025e1030.
[15] A.S. Buist, W.M. Vollmer, S.D. Sullivan, K.B. Weiss, T.A. Lee, A.M. Menezes, et
al., The Burden of Obstructive Lung Disease Initiative (BOLD): rationale anddesign, COPD 2 (2005) 277e283.
[16] R. Hooper, P. Burney, Cross-sectional relation of ethnicity to ventilatory
function in a West London population, Int. J. Tuberc. Lung Dis. 17 (2013)
400e405.
[17] J. Wanger, J.L. Clausen, A. Coates, O.F. Pedersen, V. Brusasco, F. Burgos, et al.,
Standardisation of the measurement of lung volumes, Eur. Respir. J. 26 (2005)
511e522.
[18] M.R. Miller, R. Crapo, J. Hankinson, V. Brusasco, F. Burgos, R. Casaburi, et al.,
General considerations for lung function testing, Eur. Respir. J. 26 (2005)
153e161.
[19] Reference Values for Arterial Stiffness Collaboration, Determinants of pulse
wave velocity in healthy people and in the presence of cardiovascular risk
factors: ‘establishing normal and reference values’, Eur. Heart J. 31 (2010)
2338e2350.
[20] F.U. Mattace-Raso, T.J. van der Cammen, A. Hofman, N.M. van Popele, M.L. Bos,
M.A. Schalekamp, et al., Arterial stiffness and risk of coronary heart disease
and stroke: the Rotterdam study, Circulation 113 (2006) 657e663.
[21] S. Laurent, P. Boutouyrie, R. Asmar, I. Gautier, B. Laloux, L. Guize, et al., Aortic
stiffness is an independent predictor of all-cause and cardiovascular mortality
in hypertensive patients, Hypertension 37 (2001) 1236e1241.
[22] C.P. Criee, S. Sorichter, H.J. Smith, P. Kardos, R. Merget, D. Heise, et al., Body
plethysmography e its principles and clinical use, Res. Med. 105 (2011)
959e971.
[23] K.A. Grifﬁth, D.L. Sherrill, E.M. Siegel, T.A. Manolio, H.W. Bonekat, P.L. Enright,
Predictors of loss of lung function in the elderly: the cardiovascular health
study, Am. J. Respir. Crit. Care Med. 163 (2001) 61e68.
[24] Y. van Rooyen, H.W. Huisman, A.E. Schutte, F.C. Eloff, J.L. Du Plessis, A. Kruger,
et al., South African and international reference values for lung function and
its relationship with blood pressure in Africans, Heart Lung Circ. 24 (2014)
573e582.
[25] M. Zureik, F. Kauffmann, P.J. Touboul, D. Courbon, P. Ducimetiere, Association
between peak expiratory ﬂow and the development of carotid atherosclerotic
plaques, Arch. Int. Med. 161 (2001) 1669e1676.
